Financial Performance - The company's revenue for Q1 2024 was ¥215,702,841.54, representing a 34.04% increase compared to ¥160,921,094.30 in the same period last year[5] - Net profit attributable to shareholders was ¥49,818,209.14, up 42.06% from ¥35,068,583.71 year-on-year[5] - Basic and diluted earnings per share increased by 43.75% to ¥0.4600 from ¥0.32[5] - Total operating revenue for Q1 2024 reached CNY 215,702,841.54, an increase of 34% compared to CNY 160,921,094.30 in the same period last year[20] - Net profit for Q1 2024 was CNY 49,818,209.14, compared to CNY 35,109,632.51 in Q1 2023, representing a growth of 42%[22] - The total comprehensive income for the first quarter of 2024 was CNY 49,816,859.29, compared to CNY 35,109,632.51 in the same period last year, representing an increase of approximately 41.9%[23] Cash Flow - The net cash flow from operating activities was -¥121,975,608.72, a significant decline of 3,522.23% compared to -¥3,367,415.62 in the previous year[5] - The company’s cash flow from operating activities decreased significantly due to a drop in collections and increased salary payments, leading to a net cash outflow[11] - Cash inflow from operating activities totaled CNY 110,905,629.87, down 29.2% from CNY 156,711,271.26 year-over-year[26] - Cash outflow from operating activities increased to CNY 232,881,238.59, compared to CNY 160,078,686.88 in the previous year, marking a rise of 45.3%[26] - Net cash flow from investing activities was negative CNY 233,072,878.08, worsening from negative CNY 209,284,900.00 in the same quarter last year[26] - Cash inflow from financing activities was CNY 514,000,000.00, an increase of 105.6% compared to CNY 250,000,000.00 in the previous year[26] - The ending balance of cash and cash equivalents was CNY 684,650,318.52, down from CNY 1,245,708,720.63 year-over-year[26] - The company reported a significant increase in cash paid for purchasing goods and services, totaling CNY 76,609,343.98, compared to CNY 51,869,909.38 in the previous year, reflecting a rise of 47.8%[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,834,690,944.85, a 4.51% increase from ¥3,669,106,137.11 at the end of the previous year[5] - Current liabilities increased to CNY 963,418,124.66 from CNY 846,190,707.95, marking a 14% increase[19] - The company's total liabilities reached CNY 1,093,302,422.18, up from CNY 984,969,005.99, reflecting an 11% increase[19] - The total owner's equity increased to CNY 2,741,388,522.67 from CNY 2,684,137,131.12, indicating a growth of 2%[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,849[13] - The largest shareholder, Shao Chunnan, holds 18.61% of shares, totaling 20,265,000 shares[13] - The top ten shareholders include various institutional investors, with the largest being Hangzhou Qinghai Management Consulting Partnership holding 3.40%[14] - The company has no preferred shareholders or related changes in preferred stock ownership[16] - There were no changes in the top ten shareholders due to securities lending activities[16] Research and Development - The company reported a 46.22% increase in R&D expenses, totaling ¥65,271,951.41, compared to ¥44,638,654.42 in the same period last year[10] - Research and development expenses increased to CNY 65,271,951.41, up from CNY 44,638,654.42, indicating a 46% rise year-over-year[20] Operational Highlights - The company's gross profit margin improved due to enhanced approval rates for generic drugs and increased project approvals, contributing to revenue growth[10] - The company reported a significant increase in other income, which rose by 77.16% to ¥1,195,637.89, primarily due to government subsidies related to assets[10] - Total operating costs amounted to CNY 164,553,615.62, up from CNY 125,926,754.21, reflecting a 31% increase year-over-year[20] - The financial expenses for Q1 2024 showed a significant improvement, with a net expense of CNY -1,283,729.34 compared to CNY -6,162,479.28 in the previous year[22] Audit and Reporting - The company reported no significant new strategies or product developments during the quarter[16] - The company has not undergone an audit for the first quarter report[27]
百诚医药(301096) - 2024 Q1 - 季度财报